ReviewBJOG : an international journal of obstetrics and gynaecology2017
A research agenda for moving early medical pregnancy termination over the counter.
Review in BJOG : an international journal of obstetrics and gynaecology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Self-administered versus provider-administered medical abortion.The Cochrane database of systematic reviews · 2020Pooled it
- Examining the association between prior medical mistreatment and interest in and support for over-the-counter medication abortion among people seeking in-person abortion in the United States.BMC health services research · 2026Article
- Access to medical abortion and abortion care in Japan.Preventive medicine reports · 2025Article
- Changes in Support for Advance Provision and Over-the-Counter Access to Medication Abortion.JAMA network open · 2025Article
- Comprehension of an Over-the-Counter Drug Facts Label Prototype for a Mifepristone and Misoprostol Medication Abortion Product.Obstetrics and gynecology · 2022Article
- Abortion in Countries with Restrictive Abortion Laws-Possible Directions and Solutions from the Perspective of Poland.Healthcare (Basel, Switzerland) · 2021Review
- Glancing at the past and course-setting for the future: lessons from the last decade of research on medication abortion in high-income countries.Reproductive health · 2021Review
- Observational
- A Constructivist Vision of the First-Trimester Abortion Experience.Health and human rights · 2020Article
- Commentary: No-test medication abortion: A sample protocol for increasing access during a pandemic and beyond.Contraception · 2020Article
- Developing and validating the Psychosocial Burden among people Seeking Abortion Scale (PB-SAS).PloS one · 2020Article
- Demand for Self-Managed Medication Abortion Through an Online Telemedicine Service in the United States.American journal of public health · 2020Article
- Prevalence, attitudes and knowledge of misoprostol for self-induction of abortion in women presenting for abortion at Midwestern reproductive health clinics.Sexual and reproductive health matters · 2019Article
- Motivations and Experiences of People Seeking Medication Abortion Online in the United States.Perspectives on sexual and reproductive health · 2018Article
- Medical abortions among university students in Ghana: implications for reproductive health education and management.International journal of women's health · 2018Article
- A research agenda for moving early medical pregnancy termination over the counter.BJOG : an international journal of obstetrics and gynaecology · 2017Review
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Given the overall safety profile and increasing availability of medical pregnancy termination drugs, we asked: would the mifepristone-misoprostol regimen for medical termination at ≤10 weeks of gestation meet US Food and Drug Administration regulatory criteria for over-the-counter (OTC) approval, and if not, what are the present research gaps? We conducted a literature review of consumer behaviours necessary for a successful OTC application for medical termination at ≤10 weeks of gestation and identified crucial research gaps. If we were to embark on a development programme for OTC or more generally, self-use of medical termination, the critical elements missing are the label comprehension, self-selection and actual use studies. TWEETABLE ABSTRACT: Considering medical pregnancy termination through the over-the-counter regulatory lens clarifies critical evidence gaps.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.